72 citations
,
March 2023 in “Biomolecules” Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
73 citations
,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
January 2014 in “IOSR journal of pharmacy” Adalimumab can cause complete hair loss in rare cases.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
March 2016 in “Reactions Weekly” A woman experienced hair loss, nail changes, bone marrow suppression, and low blood protein after taking azathioprine.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
35 citations
,
February 2023 in “Biomolecules” Granzyme B is important in autoimmune skin diseases and could be a new treatment target.
4 citations
,
January 2012 in “Chemical Immunology” Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
March 2026 in “Indian journal of veterinary and animal sciences research.” A Labrador Retriever with pemphigus fully recovered after six weeks of azathioprine treatment.
6 citations
,
November 2020 in “JAAD Case Reports” Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.